Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that JACC Cardiovascular Interventions published a peer reviewed article on the impact of Neovasc Reducer on ischemic burden and myocardial perfusion.
The clinical case
The JACC article is based on a 66-year-old man with a history of hypertension, dyslipidemia, multiple myocardial infarctions, and coronary artery bypass graft surgery that was presented to the treating physicians with Canadian Cardiovascular Society class III angina persisting despite optimal anti-ischemic therapy. After medical evaluation, it is decided to implantation of Reducer and the control of variations of ischemic burden and global myocardial perfusion reserve index via stress perfusion cardiac magnetic resonance (“CMR”).
Objective of the authors is to show how CMR is a useful and objective way to evaluate the impact of Neovasc Reducer on ischemic burden and myocardial perfusion.
Stress perfusion CMR is emerging as the noninvasive gold standard for the assessment of ischemia. According to the authors, the use of a reliable, non-operator-dependent imaging tool, such as stress perfusion CMR, allows for greater insights into the potential impact of the Reducer on the ischemic burden of patients with refractory angina with coronary artery disease.
At the fourth month, there is an improvement in perfusion parameters:
- ischemic burden 13.3%, down from 22.9%
- global myocardial perfusion reserve index 1.61, up from 1.25
- Seattle Angina Questionnaire domain score improvement from 45 to 73 points
The scar burden is unchanged.
The evidence of the positive impact of Reducer is that the patient is asymptomatic for angina and reported improved quality of life.
The use in this case of the CMR shows the quantified and objective improvement also of the ischemic burden and of the global myocardial perfusion reserve index.